• CDC's Advisory Committee on Immunization Practices votes to move from universal birth dosing to a selective strategy for infants of hepatitis B-negative mothers.
  • The change could affect hospital workflows, vaccine demand patterns, and long-term public-health costs, with experts warning of increased chronic infections.
  • The decision occurs amid political polarization around vaccines, with federal health leaders yet to sign off on the revised recommendation.

CDC's Advisory Committee on Immunization Practices (ACIP) has voted to drop the long-standing universal recommendation for a hepatitis B vaccine dose at birth, shifting toward a more selective approach that allows deferral for infants whose mothers test negative for the virus. According to people familiar with the matter, the committee's decision, which still requires CDC sign-off, would keep the birth-dose requirement for babies born to hepatitis B-positive mothers or those with unknown status, while encouraging parental choice and clinician-family discussion for others.

Efforts to restructure the vaccination policy have hit a snag, with infectious-disease experts and professional societies publicly warning that weakening the universal birth-dose recommendation could lead to more missed cases due to testing gaps or late maternal infection. This, in turn, might result in additional chronic hepatitis B infections and preventable liver disease and deaths later in life. Without a deal to maintain universal dosing, the U.S. could see a reversal of decades of progress in reducing early-childhood infections.

Hospital and clinic workflows are expected to face immediate impacts, with added screening, documentation, and follow-up costs to ensure timely vaccination later in infancy. Hepatitis B vaccine demand patterns may shift, potentially reducing doses given in the newborn period but emphasizing series completion and antibody testing later. Long-term public-health expenditures could rise, as increases in chronic hepatitis B would heighten future costs for monitoring, antiviral therapy, and treatment of cirrhosis and liver cancer. Global and U.S. health-economic research has repeatedly found that universal newborn hepatitis B vaccination is cost-effective or cost-saving, a backdrop against which any policy change is being assessed.

The debate is unfolding in a highly polarized environment around vaccines and public-health authority. Reports indicate that advocacy by organized vaccine-skeptic groups and political figures critical of childhood vaccination schedules has influenced pressure to reconsider long-standing recommendations. Federal health leaders must ultimately decide whether to accept, modify, or reject the ACIP recommendation, with private and public insurers typically following the official CDC schedule when setting coverage policies. Internationally, many countries follow World Health Organization guidance supporting a universal hepatitis B birth dose, especially in regions with higher endemic infection; any U.S. departure from this approach would be closely watched.

Stakeholders affected include newborns and families, who may face more complex decision-making shortly after delivery and, if uptake of later infant doses is incomplete, higher long-term infection risk. Obstetric and pediatric providers would need to navigate more nuanced consent discussions, ensure accurate maternal testing, and track infants to complete the series. Public-health agencies would have to strengthen surveillance and outreach to identify infants who miss timely vaccination or are born to mothers not correctly identified as infected. The proposal has sparked strong reactions, with intense debate over whether shifting away from universal birth dosing prioritizes parental autonomy or undermines a proven disease-prevention strategy.

In the short term, any ACIP vote to weaken the universal birth-dose recommendation is likely to lead to revised CDC guidance emphasizing maternal screening and shared decision-making. Over the longer term, modelers project that delaying or narrowing the birth-dose recommendation could increase the number of infants who become chronically infected, which in turn would mean more hepatitis B-related liver disease in adulthood. Many clinical and public-health experts predict that, if such negative outcomes materialize, pressure would mount to reinstate stronger universal policies. Parallel discussions are occurring around other vaccines in early infancy and pregnancy, where advisory bodies weigh disease burden, safety data, and political and social pressures.

Correction: An earlier version of this article stated that the universal recommendation had been fully eliminated; as of the latest publicly available information, the policy change is pending CDC sign-off and has not yet been implemented.